Skip to main content
. 2017 Aug 22;8(14):2713–2719. doi: 10.7150/jca.19458

Figure 1.

Figure 1

(A) Cellular proliferation by MTT assay with cetuximab, an AKT inhibitor (AZD5363,) and an mTOR inhibitor (everolimus). (B) Combination of cetuximab with an AKT inhibitor or an mTOR inhibitor